A shingles vaccination program in New Zealand has provided researchers with new evidence of a possible connection between the vaccine and reduced dementia risk. The latest findings, presented this week at the Clinical Trials on Alzheimer's Disease conference in Boston, showed that people who qualified for vaccination were significantly less likely to receive a dementia diagnosis over the next five years.

The analysis, led by Dr. Richard Haarburger in collaboration with researchers from Stanford University and Victoria University of Wellington, estimated that vaccination was associated with a 37.6% reduction in dementia diagnoses. Researchers calculated that the difference amounted to roughly 25 fewer cases for every 1,000 people vaccinated. Women appeared to experience a particularly strong association, and the findings covered several common forms of dementia.

The researchers took advantage of an unusual feature of New Zealand's vaccination policy. When the country introduced publicly funded shingles shots in April 2018, eligibility was limited to people ages 65 through 80. That meant someone who had recently turned 81 could not receive the publicly funded vaccine, while a person born just days later could qualify.

This narrow age cutoff allowed scientists to study two groups whose ages were nearly identical but whose access to vaccination differed. Only 0.2% of people who fell outside the eligibility range received the shot, compared with 26% of those who qualified. Researchers used the difference to estimate the vaccine's potential impact while reducing the influence of other factors that can affect dementia risk.

The New Zealand findings add to several years of research into whether shingles vaccination could have an unexpected effect on cognitive health. In April 2025, Stanford researchers published a study in Nature examining a similar vaccination policy in Wales. That investigation found a 20% reduction in dementia diagnoses among people who qualified for the vaccine over a seven-year period. Pascal Geldsetzer, the Stanford assistant professor who led the study, called the result "a really striking finding."

Additional research has reported even larger differences. A study published in Nature Communications in February 2026 compared 65,800 people who received two doses of Shingrix with more than 263,000 people who were not vaccinated. The vaccinated group had a 51% lower risk of dementia, with women again showing a stronger apparent benefit.

Researchers have also examined the relationship among elderly nursing home residents. An analysis involving more than 500,000 residents found that those who received a shingles vaccine had a 12% lower dementia risk over four years after accounting for other health conditions and factors.

The studies have attracted attention because shingles is caused by a virus that can remain in the human body for decades. The varicella-zoster virus initially causes chickenpox, but it does not disappear after the infection clears. Instead, it remains dormant in nerve cells and can reactivate later in life, causing shingles. The CDC estimates that approximately one in three Americans will develop the condition.

Scientists are investigating whether repeated or renewed activity of the virus could contribute to inflammation in the nervous system and potentially affect the brain. Vaccination may reduce that risk by preventing shingles outbreaks. Researchers are also considering whether the immune response produced by the vaccine could have benefits independent of preventing the infection itself.

The precise explanation remains unknown, and scientists have not established that the vaccine directly prevents dementia. Helen Petousis-Harris, a vaccinologist and associate professor at the University of Auckland, said the evidence is becoming more compelling but cautioned against concluding what the studies demonstrate.

"I wouldn’t say the shingles vaccine prevents dementia because the evidence does not support that claim yet. But the evidence that it may also be doing something beneficial for brain health is getting stronger," she said in a September 2026 university report.

The CDC currently recommends two doses of Shingrix for adults 50 and older, with the shots generally given two to six months apart. Adults 19 and older with weakened immune systems due to disease or medical treatment are also advised to receive the vaccine. Shingrix is more than 90% effective at preventing shingles and postherpetic neuralgia, a complication that can cause persistent nerve pain for months or years.

The recommendation also applies to people who have already experienced shingles or previously received Zostavax, an older vaccine that is no longer available in the United States. Researchers hope further investigations will clarify whether the apparent reduction in dementia risk is consistent across populations and whether preventing shingles is directly responsible for the difference. Until then, the vaccine's established role remains protecting eligible adults against shingles, with a possible benefit for brain health still under investigation.